Identification of novel prostate cancer-associated antigens through antibody profiling of prostate cancer patients treated with CTLA-4 blockade. Read more about Identification of novel prostate cancer-associated antigens through antibody profiling of prostate cancer patients treated with CTLA-4 blockade.
Effect of screening on the detection of good and poor prognosis breast cancers. Read more about Effect of screening on the detection of good and poor prognosis breast cancers.
Interim results of a phase I trial of intraventricular rituximab plus methotrexate in recurrent CNS lymphoma: Macrophage polarization and acquired resistance to therapy. Read more about Interim results of a phase I trial of intraventricular rituximab plus methotrexate in recurrent CNS lymphoma: Macrophage polarization and acquired resistance to therapy.
Evaluation of levels of proliferating macrophages in patients at a county hospital and those with early recurrences. Read more about Evaluation of levels of proliferating macrophages in patients at a county hospital and those with early recurrences.
The risk of hepatocellular carcinoma in patients with previous malignancy. Read more about The risk of hepatocellular carcinoma in patients with previous malignancy.
Treatment of primary CNS lymphoma with induction high-dose methotrexate, temozolomide, rituximab followed by consolidation cytarabine/etoposide: A pilot study with biomarker analysis. Read more about Treatment of primary CNS lymphoma with induction high-dose methotrexate, temozolomide, rituximab followed by consolidation cytarabine/etoposide: A pilot study with biomarker analysis.
Solid organ second malignant neoplasms among children diagnosed with malignant bone tumors treated on Children Cancer Study Group/Pediatric Oncology Group protocols after 1980. Read more about Solid organ second malignant neoplasms among children diagnosed with malignant bone tumors treated on Children Cancer Study Group/Pediatric Oncology Group protocols after 1980.
Temozolomide and intravenous irinotecan for refractory Ewing’s sarcoma: A retrospective review. Read more about Temozolomide and intravenous irinotecan for refractory Ewing’s sarcoma: A retrospective review.
